BlueCrest Capital Management’s Antares Pharma, Inc. ATRS Stock Holding History

BlueCrest Capital Management’s Portfolio ATRS Stock Details ATRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-14,019	Closed	-$31K	–	1949
2018 Q1	$31K	Buy	+14,019	New	+$31.6K	﹤0.01%	1436
2017 Q4	–	Sell	-12,019	Closed	-$39K	–	1173
2017 Q3	$39K	Buy	+12,019	New	+$37.1K	﹤0.01%	817
2017 Q2	–	Sell	-151,730	Closed	-$431K	–	1166
2017 Q1	$431K	Buy	+151,730	New	+$365K	0.02%	458

Other funds holding ATRS

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MWP

MYCIO Wealth Partners Philadelphia, Pennsylvania $502M AUM 11.65% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlueCrest Capital Management's ATRS Position: Q2 2018 in Review

BlueCrest Capital Management sold out of Antares Pharma, Inc. (ATRS) in Q2 2018, closing a stake of 14,019 shares — an estimated $31K sold.

BlueCrest Capital Management first reported a position in ATRS in Q1 2017 and held it in 3 quarters. The position peaked at $431K in Q1 2017. 101 funds tracked by Wall St. Rank hold ATRS as of Q2 2018.

BlueCrest Capital Management reported no remaining Antares Pharma, Inc. position as of Q2 2018 after selling out during the quarter.
BlueCrest Capital Management sold 14,019 Antares Pharma, Inc. shares in Q2 2018, an estimated $31K.
BlueCrest Capital Management first reported a position in Antares Pharma, Inc. in Q1 2017 and held it in 3 quarters.
BlueCrest Capital Management's Antares Pharma, Inc. position peaked at $431K in Q1 2017.
101 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q2 2018.

Based on BlueCrest Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.